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University of Wisconsin, Madison
We develop a model-based methodology for integrating gene-set
information with an experimentally-derived gene list. The method-
ology uses a previously reported sampling model, but takes advan-
tage of natural constraints in the high-dimensional discrete parame-
ter space in order to work from a more structured prior distribution
than is currently available. We show how the natural constraints are
expressed in terms of linear inequality constraints within a set of bi-
nary latent variables. Further, the currently available prior gives low
probability to these constraints in complex systems, such as Gene
Ontology (GO), thus reducing the efficiency of statistical inference.
We develop two computational advances to enable posterior infer-
ence within the constrained parameter space: one using integer lin-
ear programming for optimization and one using a penalized Markov
chain sampler. Numerical experiments demonstrate the utility of the
new methodology for a multivariate integration of genomic data with
GO or related information systems. Compared to available methods,
the proposed multi-functional analyzer covers more reported genes
without mis-covering nonreported genes, as demonstrated on genome-
wide data from association studies of type 2 diabetes and from RNA
interference studies of influenza.
1. Introduction. In statistical genomics, the gene list is a recurring data
structure. We have in mind situations where experimental results amount
to a collection of genes measured to have some property. Examples include
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the following: RNA expression studies, in which the property might be dif-
ferential expression of the gene between two cell types; genome-wide RNA
knock-down studies, in which the property is significant phenotypic alter-
ation caused by RNA interference; chromatin studies recording genes in the
vicinity of transcription factor binding sites or having certain epigenetic
marks. In all cases, the reported gene list is really the result of inference
from more basic experimental data. These more basic data may be available
to support subsequent analyses, but we are concerned with the important
and relatively common case in which the gene list itself is the primary data
set brought forward for analysis.
The statistical question of central importance in the present paper is how
to interpret the gene list in the context of preexisting biological knowledge
about the functional properties of all genes, as these exogenous data are
recorded in database systems, notably Gene Ontology (GO), the Kyoto En-
cyclopedia (KEGG) and the reactome, among others [The Gene Ontology
Consortium (2000); Kanehisa and Goto (2000); Matthews et al. (2009); Gen-
tleman et al. (2004)]. For us, exogenous data form a collection of gene sets,
with each set equaling those genes previously determined, by some evidence,
to have a specific biological property. Recently, for example, the full GO col-
lection contained 16,527 sets (GO terms) annotating 17,959 human genes.5
Needless to say, genes are typically annotated to multiple gene sets (median
7 sets per gene among the genes annotated to sets which contain between
3 and 30 genes, e.g.), covering all sorts of functional properties. The task
of gene-set analysis is to efficiently interpret the functional content of an
experimentally-derived gene list by somehow integrating these endogenous
and exogenous data sources [Khatri, Sirota and Butte (2012)].
Our starting point is an exciting development in the methodology of
gene-set analysis. Model-based gene-set analysis (MGSA) expresses gene-
level indicators of presence on the gene list as Bernoulli trials whose success
probabilities are determined in a simple way by latent activity states of bi-
nary variables associated with the gene sets [Bauer, Gagneur and Robinson
(2010); Bauer, Robinson and Gagneur (2011)]. Inference seeks to identify
the active gene sets, as these represent functional drivers of the experimen-
tal data. Inference is computationally difficult because the activity state of a
given gene set depends not only on experimental data for genes in that set,
but also on the unknown activity states of all other gene sets that annotate
these same genes. MGSA overcomes the problem through Bayesian inference
implemented with an efficient Markov chain Monte Carlo (MCMC) sampler,
and thus provides marginal posterior probabilities that each gene set is in
the active state. The MGSA methodology is compelling. Because it treats
5Bioconductor package org.Hs.eg.db, version 2.8.0.
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all gene sets in the collection simultaneously, it provides a truly multivari-
ate analysis of the exogenous data source, where most available approaches
are univariate (one set at a time). Where set/set overlaps are a nuisance
in most gene-set methodologies, MGSA utilizes them directly in modeling
and inference. This accounts for pleitropy, that genes have multiple biologi-
cal functions, reduces the risk of spurious associations, and leads to cleaner
output whereby a typical list of gene sets inferred to be active is simpler
and exhibits less redundancy than in standard univariate analyses [Bauer,
Gagneur and Robinson (2010); Newton, He and Kendziorski (2012)].
Our analysis reveals a feature of MGSA that adversely affects its sta-
tistical properties. In ever denser collections of gene sets, the MGSA prior
distribution puts more and more mass on logically inconsistent joint ac-
tivity states. As a result, data need to work ever harder to overcome this
misguided prior probability. The effect is tangible; for a given amount of
data, fewer truly activated gene sets are inferred to be active, compared
to what is achievable with an alternative formulation. We propose a new
methodology, the multi-functional analyzer (MFA), which aims to improve
the statistical efficiency of MGSA. It uses two computational advances that
enable posterior inference in the high-dimensional constrained space of joint
activity states. One is an efficient MCMC sampling scheme constructed by
penalizing the log-posterior in the unconstrained space and one is a discrete
optimizaton scheme that translates the inference problem into an integer
linear programming (ILP) problem.
We note that inference about gene-set activity states may be interest-
ing from the general perspective of high-dimensional statistics. Typically,
dependence among data from different inference units (sets, in this case)
is considered a nuisance and testing aims to identify nonnull units (active
sets) by some methodology that is robust to dependencies, since these de-
pendencies are often difficult to estimate from available data. In the present
context dependencies are complicated but explicit, and inference benefits by
using them to advantage. Finally, we also note that the probability model
underlying our methodology—the role model—has potential utility in other
domains of application. It provides a simple way to relate data collected at
one level (genes, in this case) to inference units that are unordered collections
of the former (gene sets, in this case).
2. Role model.
2.1. Model. Following the description in Newton et al., we have a finite
number of parts p and a finite number of wholes w, where each whole is an
unordered set of parts. The incidence matrix I = (Ip,w) is determined from
external knowledge, where Ip,w = 1 if and only if p ∈w. The intended corre-
spondence is that genes are parts and gene sets (i.e., functional categories)
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are wholes. The matrix I encodes a full collection of gene sets. We will have
measured data on the parts and aim to make inference on properties of the
wholes.
The experimentally-derived gene list may be viewed as a vector of Bernoulli
trials X = (Xp), with Xp = 1 if and only if part (gene) p is on the list. First
proposed in Bauer, Gagneur and Robinson (2010), the role model describes
the joint distribution of X in terms of latent binary (0/1) activity variables
Z = (Zw) and by part-level activities induced by them: Ap = 1 if Zw = 1 for
any w with p ∈w or, equivalently,
Ap = max
w : p∈w
Zw.(2.1)
This conveys the simple assumption that a part is activated if it is in any
whole that is activated. For false-positive and true-positive parameters α,γ ∈
(0,1), with α< γ, the model for X entails mutually independent components
(conditionally on latent activities), with
Xp ∼ Bernoulli
{
α, if Ap = 0,
γ, if Ap = 1.
(2.2)
Simply, activated parts (i.e., those with Ap = 1) are delivered to the list at a
higher rate than inactivated parts. A key feature of the model is that a part
(gene) is activated by virtue of any one of its functional roles; this implies
that a gene may be activated and yet be part of a functional category that
is inactivated, which is in contrast to most other gene-set inference meth-
ods [e.g., Goeman and Bu¨hlmann (2007); Barry, Nobel and Wright (2008);
Sartor, Leikauf and Medvedovic (2009)] and which provides for a fully mul-
tivariate analysis of the gene list. In Bauer, Gagneur and Robinson (2010)
it is further assumed, for the sake of Bayesian analysis, that uncertainty in
whole-level activities is represented with a single rate parameter pi ∈ (0,1):
Zw ∼i.i.d. Bernoulli(pi).(2.3)
Taken together, the model (2.2) and the prior (2.3) determine a joint poste-
rior for Z given X . The R package MGSA (model-based gene-set analysis) re-
ports MCMC-computed marginal posterior probabilities P (Zw = 1|X), also
integrating uncertainty in the system parameters α, γ and pi, and thus pro-
vides a useful ranking of the wholes [Bauer, Robinson and Gagneur (2011);
R Development Core Team (2011)].
In addition to the system incidence matrix I , a useful data structure for
computations turns out to be the bipartite graph G, having whole nodes
and part nodes, and an edge between w and p if and only if Ip,w = 1 (i.e., iff
p ∈w).
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2.2. Activation hypothesis. As defined above, the role model allows that
a whole can be inactive while all of its parts are active. This can happen
because of overlap among the wholes. Specifically, if w is contained in the
union of other wholes {w′}, then all Zw′ = 1 will force Ap = 1 for all p ∈w,
regardless of the value of Zw. This rather odd situation calls into question
the meaning of active and what we might realistically expect can be inferred
from data. Indeed, the issue is related to identifiability of the activity vector
Z, since it shows that distinct Z vectors may produce the same part-level
activity vector A = (Ap). (In the case above, switching Zw from 0 to 1
does not change A.) The mapping Z −→A given by (2.1) is not necessarily
invertible, depending on the system as defined in I . Lack of identifiability
would not necessarily create difficulty in a Bayesian analysis, however, in the
present case we are specifically interested in inferring the activity states of
the gene sets and prioritizing these sets, and so it stands to reason that we
ought to confer a real, if still only model-based, meaning on the activities.
When activity is defined more fully, there is a simple solution to the
problem. The activation hypothesis asserts that a set of parts is active if
and only if all parts in the set are active. It was shown previously (Newton
et al.) as follows:
Theorem 2.1. Under the activation hypothesis (AH), the mapping Z −→
A defined by
Ap = max
w : p∈w
Zw
is invertible, with inverse A−→ Z
Zw = min
p : p∈w
Ap.
The inverse mapping is simply that a whole is inactive if and only if any of
its parts is inactive. So the odd case at the beginning of the section cannot
occur under AH; if all parts are active, then Zw = 1 must hold. Further,
with parameters α and γ fixed, the Z vector is identifiable under AH, since
different Z vectors necessarily give different probability distributions to data
X .
The first contribution of the present work is to show that the activation
hypothesis is equivalent to a set of linear inequality constraints on the ac-
tivity variables. The finding is useful for posterior inference computations.
We prove in Section 7 the following:
Theorem 2.2. AH holds if and only if all of the following hold:
1. Zw ≤Ap for all p,w with p ∈w;
2. Ap ≤
∑
w : p∈wZw for all p;
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3.
∑
p : p∈w(Zw − 2Ap + 2)≥ 1 for all w.
Evidently, the i.i.d. Bernoulli prior (2.3) does not respect AH in the sense
that vectors Z which violate AH have positive prior probability. In simple
systems such violation may be innocuous. We provide evidence that in the
complex systems such as GO, this violation creates a substantial loss of
statistical efficiency. We note first that alternative prior specifications are
available that respect AH. A simple one is to condition prior (2.3) on the
AH event, namely,
P (Z = z) =
(
1
c
)
pi
∑
w
zw(1− pi)
∑
w
(1−zw) if z satisfies AH,(2.4)
otherwise P (Z = z) = 0, where c is the probability, in prior (2.3), that Z
satisfies AH, and z is a vector of binaries representing a possible realization
of Z. In other words, with subscript “1” for the i.i.d. prior (2.3) and “2” for
prior (2.4), we have P2(Z = z) = P1(Z = z|AH). Upon conditioning, the (Zw)
are not necessarily either mutually independent or identically distributed.
3. Statistical properties. The role of the prior distribution in Bayesian
analysis has surely been the subject of considerable debate. On the one
hand, it helps by regularizing inference, especially in high dimensions. On
the other hand, data need to work against it to produce inferences that trade
off empirical characteristics with prior assumptions. A fact of relevance to
the present problem is that gene-list data must work against either prior
[(2.3) or (2.4)] to deliver an inferred list of activated gene sets. For two
Bayesian analysts, one using prior (2.3) and the other using prior (2.4),
the true state is ascribed different prior mass. The ratio of these masses, ρ,
represents the extra effort needed to be done by the data to overcome prior
(2.3) compared to prior (2.4):
ρ=
P2(Z = ztrue)
P1(Z = ztrue)
=
P1(Z = ztrue|AH)
P1(Z = ztrue)
=
1
P1(AH)
≥ 1.(3.1)
Here we have used the particular structure of prior (2.4) and also the as-
sumption that ztrue satifies AH. If ztrue did not satisfy AH, the target of
inference would be beyond the realm of any gene-level data set to estimate,
owing to lack of identifiability. Indeed, it is difficult to see what meaning
could be ascribed to ztrue in that case. The observation to be gained from
(3.1) is that the probability of AH under the i.i.d. prior affects the effi-
ciency of inference. In systems where that probability is very small, there
is reason to believe that improved inferences are possible. As to the pre-
cise effect of ignoring AH, that depends on the particular system I , the
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true activation state, and the system parameters α and γ. What our ini-
tial investigation finds is that a truly activated whole w may tend to have
P1(Zw = 1|X) smaller than P2(Zw = 1|X), and if so the P1 inference is too
conservative.
Whether or not AH holds for a given state Z may be assessed by calculat-
ing the part-level activities A and then checking Theorem 2.2. Alternatively,
we consider whole-level violation variables (Vw). These Bernoulli trials are
defined as follows:
Vw =


1, if Zw = 0 and if for all p ∈w there exists w
′
with p ∈w′ and Zw′ = 1,
0, otherwise.
(3.2)
The probability, under P1, that Z satisfies AH is equivalent to the probability
of no violations, that is,
P1(AH) = P1(Vw = 0,∀w),(3.3)
and so AH probability might be approachable by considering the violation
variables. Except in stylized examples, we do not expect these variables to
be mutually independent; indeed, they may have a complicated dependence
induced by overlaps of the wholes and, hence, direct calculation of P1(AH)
is intractable. However, the expectations of Vw are readily computable for
a given system, either by Monte Carlo or by a more sophisticated algo-
rithm [Wang et al. (2014)]. Considering the Chen–Stein result for Poisson
approximations, we conjecture that − logP1(AH) is approximately equal to
E1(
∑
w Vw), though we have not been able to guarantee an error on this
approximation [cf. Arratia, Goldstein and Gordon (1990)].
Figure 1 charts the expected value E1(
∑
w Vw) over four recent versions
of Gene Ontology, for pi = 1/100. For concreteness it focuses on GO terms
holding between 5 and 20 genes (for which an exact calculation of the expec-
tation is feasible), though the key finding is not sensitive to that restriction,
as evidenced by Monte Carlo computations (not shown). As one might ex-
pect by the increasing density and complexity of GO, the expected number
of AH violations increases. This may very well reflect the fact that P1(AH)
is decreasing over time, which indicates to us that ignoring AH is becoming
an ever greater problem for gene-set analysis.
In terms of modeling assumptions, there is no additional cost to account-
ing for AH in the Bayesian analysis; the cost is purely computational, since
inference must now deal with the constraints imposed by AH on the space
of latent activities. The next sections describe two computational advances
that address the problem.
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Fig. 1. Expected number of sets that violate the activation hypothesis (AH) for four recent
versions of Gene Ontology (GO), considering sets holding between 5 and 20 genes, taken on
the i.i.d. Bernoulli prior. Calculations are done at pi = 1/100. Respectively, these systems
contain 3591, 4096, 4449 and 4772 gene sets, and correspond to versions of org.Hs.eg.db.
4. Decoding functional signals via constrained optimization.
4.1. MAP via ILP. Decoding a discrete signal is frequently accomplished
by algorithms that compute the parameter state having the highest poste-
rior mass: the maximum a posteriori (MAP) estimate. Although limited
as a posterior summary, the MAP estimate may contain useful multivari-
ate information [e.g., Carvalho and Lawrence (2008)]. Our representation
of model-based gene-set analysis reveals that under model (2.2) and prior
(2.4), the log posterior is linear in the joint collection of whole and part
activity variables. This log posterior is
l(Z,A) =
∑
w
{Zw log(pi) + (1−Zw) log(1− pi)}
+
∑
p
{Ap[xp log(γ) + (1− xp) log(1− γ)](4.1)
+ (1−Ap)[xp log(α) + (1− xp) log(1− α)]},
where xp is the realized value of the gene-list indicator Xp, and α, γ, and
pi are system parameters, which are considered fixed in the present calcula-
tion. Considering Theorem 2.2, finding the MAP estimate (Zˆ, Aˆ) amounts to
maximizing a linear function in discrete variables subject to linear inequality
constraints. As such, it fits naturally into the domain of integer linear pro-
gramming (ILP), an active subfield of optimization. Our computations take
advantage of ILP software available in the GNU Linear Programming Kit
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through its interface with R.6 We employed a series of basic code checks to
assure our implementation worked in: (1) simple examples where the MAP
estimate is computable by other means; and (2) limiting situations where Xp
was Binomial having a high sample size, and thus where the MAP estimate
must converge to the true activity state.
The reconstruction Zˆ obtained through this optimization holds an es-
timate of the activated and inactivated gene sets. We refer to the overall
method as the multi-functional analyzer (MFA), and specifically MFA-ILP
to refer to the posterior mode computed by ILP. We note that by invertibil-
ity of the mapping Z −→A under AH, the log-posterior l could be expressed
either as a function of Z only or as a function of A only, however, in nei-
ther reduced case would l be linear in the input variables. Moreover, in
neither reduced case could the constraints be expressed as linear inequality
constraints. By expanding the domain we formulate the constrained opti-
mization as an integer linear program.
4.2. Numerical experiments. In each experiment reported below we rep-
resented a system with a parts-by-wholes incidence matrix I ; we fixed the
false-positive rate α= 1/10 and the true positive rate γ = 9/10. We simu-
lated 100 gene-lists X from model (2.2), each time using a simulated activity
vector Z. For methods comparison, we applied the following: (1) the com-
monly used Fisher exact test for enrichment of each gene set in the data X
[Khatri, Sirota and Butte (2012)], (2) MGSA (version 1.7.0), and (3) MFA-
ILP. We allowed both model-based methods to know the system parameter
settings. To evaluate performance, we calculated specificity, sensitivity, and
precision of the estimated activity vector Zˆ for the true activity vector Z
by averaging over the 100 replicates.
Experiment 1: Low overlap. Initially, I had size 300 genes (parts) by
100 gene sets (wholes). We randomly picked 5 and 10 parts for each whole
in columns 1–50 and 51–100, respectively. Then we removed parts not con-
tained by any whole, leaving a 296 × 100 incidence matrix. We sampled
Z from prior (2.3) and then projected it onto AH by constructing Ap =
maxw : p∈wZw and then updating Zw = minp : p∈wAp. All methods exhibit
similar operating characteristics in this case (Table 1).
Experiment 2: Higher overlap and parent-child structure. Initially, I had
size 300 parts by 105 wholes. From column 1 to column 20, each column has
20 parts, of which 15 parts are in common with each other and 5 parts are
randomly selected from the other parts; column 21 has 10 parts which are
6See www.gnu.org/software/glpk and cran.R-project.org/package=Rglpk.
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Table 1
Simulation comparison of three gene-set methods, a case of low overlap among gene sets:
Tabulated are mean values from 100 simulated data sets. On average 7.3 truly activated
sets occur
Method Predicted # active Sensitivity Specificity Precision
MFA-ILP 7.4 0.963 0.997 0.958
Fisher (cut-off = 0.05) 5.9 0.790 0.998 0.966
Fisher (cut-off = 0.1) 6.8 0.873 0.996 0.948
MGSA (cut-off = 0.5) 7.2 0.954 0.998 0.968
randomly picked from the 15 common parts shared by columns 1–20. Thus,
columns 1–20 have a lot of overlaps and column 21 is a child of columns 1–20.
Similarly, we built columns 22–42, 43–63, 64–84 and 85–105. The common 15
parts in each column combination are all different. Then parts not contained
by any whole were removed, which resulted in a 265× 105 incidence matrix.
We activated wholes by sampling one whole from columns 1–20, 22–41, 43–
62, 64–83 and 85–104 as activated, respectively, and projected onto AH as
above.
Table 2 exhibits properties of three methods in relatively complicated sys-
tem just defined. The univariate Fisher test tends to select the wholes with
a high correlation (overlap) with the truly activated wholes, which results
in high sensitivity but low specificity (or precision). The extra activation
calls correspond to spurious associations that the multivariate, model-based
approaches are able to recognize. The MGSA method often fails to discover
truly activated wholes, which corresponds to a reduced sensitivity. The small
child wholes tend to be missed by MGSA in this case. The proposed MFA-
ILP method is right on target.
4.3. ILP for large systems. Large systems strain unaided ILP compu-
tation, but the special structure of the gene-set problem allows for several
refinements.
Table 2
Simulation comparison of three gene-set methods, a case of higher overlap among gene
sets: Tabulated are mean values from 100 simulated data sets. On average there are 10.1
truly activated sets in this case
Method Predicted # active Sensitivity Specificity Precision
MFA-ILP 10.2 0.975 0.997 0.993
Fisher (cut-off = 0.05) 104.2 0.996 0.008 0.096
Fisher (cut-off = 0.1) 104.8 0.996 0.002 0.096
MGSA (cut-off = 0.5) 5.5 0.490 0.995 0.920
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Shrinking I. Up to a constant, the objective function in (4.1) may be
expressed
l(Z,A) = c1
∑
w
Zw + c2
∑
p∈P−
Ap + c3
∑
p∈P+
Ap,
where
c1 = logpi− log(1− pi),
c2 = log(1− γ)− log(1− α),
c3 = log γ − logα
and where P− and P+ denote the observed inactivated and activated parts,
respectively. That is, p ∈ P− if xp = 0 and p ∈ P
+ if xp = 1. By assump-
tion (2.2), α< γ and so c2 < 0 and c3 > 0. If we further insist that pi < 1/2,
then c1 < 0 also. In some cases we can know which Zˆw and Aˆp must equal 0
in the optimal solution, and if so we can remove these variables from the sys-
tem prior to implementing ILP. For each whole w denote P+w =w ∩P
+ and
similarly P−w =w ∩P
−, and define W ∗ = {w : c1 + c3
∑
p∈P+w
1< 0}. Clearly,
those wholes containing no reported parts are in W ∗, but there may be oth-
ers. We prove in Section 7 that if W ∗ is not empty, then we may be able to
shrink the system prior to solving the constrained optimization problem via
ILP.
Theorem 4.1. Suppose pi < 1/2 and let w0 denote an element of W
∗.
If there exists p0 ∈w0 such that {w :p0 ∈w} ⊂W
∗, then Zˆw0 = Aˆp0 = 0.
Letting W0 and P0 denote wholes and parts for which the optimal solu-
tion is known (in advance of computation), we may remove these from the
incidence matrix I , effectively shrinking it. The amount of shrinkage may be
dramatic, but it depends on the observed data x, the system I , and system
parameters α, γ and pi. When α is small and γ is large, the effects may be
minimal.
A sequential approach. In the unlikely event that the system matrix I
is separable into blocks of wholes that do not overlap between blocks, then
ILP may be applied separately to these distinct blocks in order to identify
the MAP activities. We do not expect this separability in GO or related
systems, but we can take advantage of size variation of the wholes and work
sequentially from small ones to larger ones. As an example, let S10 denote
the sets containing no more than n.up = 10 genes. In order to obtain the
optimal solution for the full problem, we start from the sub-matrix I.10
obtained by extracting these sets from I . Suppose Z∗10 is the MAP solution
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based on the data for I.10, and use notation S∗10 to denote the active sets
in S10 as inferred by Z
∗
10. We aim to find the optimal solution Z
∗
11 for I.11
using what has already been computed in the smaller system. Denote the
newly added sets in I.11 by S1110 (i.e., the sets containing exactly 11 genes).
We just need to consider the sets with the possibility being active in the
optimal solution on I.11. First of all, S∗10 and S
11
10 should be included, in the
case we have no any other prior knowledge about Z∗11. Second, by the 3rd
AH inequality (Theorem 2.2), any set in S10 \S
∗
10 which is a subset of some
set in S1110 , denoted by D, should also be included. But these sets already
considered are not enough. Actually, for each set w1 in S
11
10 , we need to check
whether there exists some set w2 in S10 \ (S
∗
10 ∪D) satisfying
c1 + c2
∑
p∈P−∩P
w2
w1
Ap + c3
∑
p∈P+∩P
w2
w1
Ap > 0,(4.2)
where Pw2w1 denote the set of genes contained by w2 and not by w1. We do this
since each set in S1110 may be active in the optimal solution Z
∗
11, and we need
to check whether some sets in S10 should be activated toward maximizing
the objective function. We denote the sets in S10 \ (S
∗
10 ∪D) satisfying the
condition (4.2) by E. Finally, by the 3rd AH inequality (Theorem 2.2), any
set in S10 \ (S
∗
10 ∪D ∪ E) which is a subset of some set in E, denoted by
F , should also be included. Thus, we need to run the ILP on the incidence
matrix only for S∗10 ∪ S
11
10 ∪D ∪E ∪ F , instead of I.11. Hence, we obtain a
sequential approach to solve the full ILP problem from a sequence of smaller
problems. Examples show this is feasible in GO for subsystems holding sets
of up to 50 genes, without excessive computational burden.
5. Posterior sampling.
5.1. Penalized MCMC. To obtain a sample from the posterior distri-
bution defined by prior (2.4) and model (2.2) in which the whole activity
variables Z = (Zw) have positive probability only when Z satisfies AH, we
design a Markov chain to run within the unconstrained space according to
a penalized posterior:
l˜(Z) = l(Z,A)− λ
∑
w
Vw,(5.1)
where l(Z,A) is defined in (4.1), Vw is the violation indicator (3.2), and
λ≥ 0 is a tuning parameter. The desired sample is obtained by discarding
any sampled states that do not satisfy AH. Note that there are no violations
(
∑
w Vw = 0) for Z that satisfy AH, so that l˜(Z) = l(Z,A) in this case and the
conditional log posterior distribution under l˜(Z) restricted to AH is identical
to the target log posterior distribution. Increasing the tuning parameter λ
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increases the probability of AH in the larger state space, which is essential for
efficient sampling when this probability is small. We find that penalizing the
log posterior within the unconstrained space leads to a conditional sampler
that mixes well in the constrained space, where our previous attempts to
constrain move types were less successful.
It is helpful to visualize the Markov chain as operating by changing colors
on the node-colored bipartite graph G having whole nodes and part nodes,
with an edge between a whole node w and part node p if and only if p ∈w,
and where the coloring of the whole nodes {w} and part nodes {p} match
the activities Z and A, respectively. It is useful in assessing the state of
the Markov chain to associate with each node a count n(·) of its active
connected neighbors in G. Ap = 1 if and only if n(p)> 0 and Vw = 1 if and
only if Zw = 0 and n(w) = deg(w), the number of part nodes p ∈w.
The Markov chain proceeds by selecting at random a whole node w and
proposing a color swap (a change in the status of the activity variable, Z∗w =
1−Zw) for this node.
7 This proposed change can, but need not, affect the
activities of parts contained in this whole. When Z∗w = 1, the active neighbor
counts n(p) increase by 1 for each p ∈w. If Ap changes from 0 to 1, then each
node w′ that contains p (including w) gains an additional active neighbor
and n(w′) increases by 1. This increase could cause a violation if p were the
only remaining inactive neighbor of an inactive w′, causing Vw′ to change
form 0 to 1. If node w were in violation before this proposal, activating it
would eliminate the violation. Similarly, when Z∗w = 0, the active neighbor
counts n(p) decrease by 1 for each p ∈ w. If this decrease is from 1 to 0,
then the activity Ap changes from 1 to 0 as well and all of the whole nodes
w′ connected to p would lose an active neighbor, n(w′) decreasing by 1. If
the whole node w′ had been in violation, this change would eliminate the
violation with Vw′ changing from 1 to 0.
Careful accounting of the changes to a few key counts allows for quick
calculation of the change in l˜(Z∗) and subsequent acceptance or rejection of
the proposal by Metropolis–Hastings. The log posterior l˜(Z∗) is a function
of α, γ, pi, the penalty λ and the counts of the numbers of active and inactive
whole nodes [
∑
wZw and
∑
w(1−Zw), resp.], the number of whole nodes in
violation (
∑
Vw), the numbers of active part nodes with realized values 1
and 0 [
∑
pApxp and
∑
pAp(1−xp), resp.], and the numbers of inactive part
nodes with realized values 1 and 0 [
∑
p(1−Ap)xp and
∑
p(1−Ap)(1− xp),
resp.].
7Efficiency gains may be possible by using a nonuniform sampler, for instance, depend-
ing on the set size or the number of reported parts in the whole, though we use a uniform
proposal in the present work.
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5.2. Numerical experiment. To assess the performance of MFA-MCMC,
we simulated gene-list data according to the role model in theD. melanogaster
genome, following the scheme presented in Bauer, Gagneur and Robinson
(2010). Briefly, we used 3275 GO terms annotating between 5 and 50 fly
genes, according to version 2.14.0 of Bioconductor package org.Dm.eg.db.
In each simulation run, a number of GO terms were activated and then a
gene list was constructed from independent Bernoulli trials depending on the
activation states and settings of false-positive and false-negative error rates.
Figure 2 shows receiver-operating (ROC) curves and precision-recall curves
for two parameter settings, based on 100 simulated gene lists in each setting.
Selection to the reported set list is based on thresholding the marginal pos-
Fig. 2. Operating characteristics of MFA-MCMC, MGSA, and Fisher’s test based on
simulating the role model in the D. melanogaster genome.
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terior probability (MGSA, MFA-MCMC) or the p-value (Fisher). Evidently,
MGSA and MFA-MCMC are accurate and show similar behavior when error
rates are low, though MFA-MCMC shows improved precision and sensitivity
in more difficult settings.
In subsequent calculations we deploy both MAP estimation (MFA-ILP)
and MCMC sampling on each data set in order to infer wholes that are prob-
ably activated. For MCMC, we use 107 sweeps, burn-in of 106, and λ= 5,
which causes about one third of the states to satisfy AH. MFA-ILP gives a
summary functional decoding of the gene list. Posterior probabilities from
the MCMC computation provide a measure of confidence in the inferred sets
and also highlight notable non-MAP sets. Fisher’s test is the default uni-
variate method for gene-list data; we include it for comparison, even though
the hypotheses it tests are different from the activation states assessed by
MFA and MGSA.
6. Examples.
6.1. Genes implicated in type 2 diabetes (T2D). From a large-scale genome-
wide association study (GWAS) involving more than 34,000 cases and 114,000
control subjects, 77 human genes have been implicated as affecting T2D dis-
ease susceptibility [Morris et al. (2012), Supplementary Table 15, primary
list]. To assess the functional content of this gene list, we applied MFA,
MGSA, and simple enrichment via Fisher’s exact test, all in the context of
6037 gene ontology terms, each annotating between 5 and 50 genes.8 Here
and in other examples we took advantage of available information on likely
false positive (α) and false negative (1 − γ) error rates at the gene level.
Using the fitted mixture model from Morris et al., we estimated α= 0.00019
and γ = 0.02279 for this large-scale GWAS [details in Wang et al. (2014)].
Figure 3 summarizes the application of MFA, MGSA, and Fisher’s test
to this example. Table 3 reports those gene sets inferred by MFA-ILP to be
activated in T2D. Tables S1–S4 provide further information for comparison
of MFA with MGSA and Fisher’s test [Wang et al. (2014)]. The example
illustrates features we see repeatedly with these methods. Sets identified by
Fisher’s test tend to overlap substantially, reflecting the univariate nature of
the approach; both MGSA and MFA-ILP alleviate this redundancy problem,
but MGSA finds fewer sets than MFA-ILP. As expected, each of the 11 sets
inferred by the ILP algorithm (i.e., the MAP estimate of the activated sets)
has high marginal posterior probability of activation (P.MFA). Furthermore,
MFA-ILP is able to explain more of the gene level findings than the other
8These 6037 terms annotate a total of 10,626 genes; among the 77 T2D-associated
genes, 58 are in this moderately annotated class.
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Fig. 3. GO terms inferred by three methods (A, Fisher’s test; B, MGSA; C, MFA-ILP)
to be activated to explain the type 2 diabetes associated genes (58 of the 77 are annotated to
the 6037 GO terms used). Panels are linked by the location of sets; three sets (black) were
identified by multiple methods. GO ID is on the outer rim, and sets are ordered by size
as in Tables 3 and S1–S3, from largest (noon) and decreasing clockwise; numbers inside
circles indicate the number of T2D genes annotated to that set; a line connects two sets
if their intersection contains at least one T2D-associated gene. The total number of T2D
genes explained by the identified sets (coverage), lower right, as a subset of the 58 starting
genes. Similarly, the mis-coverage (mcov) counts the number of genes within the inferred
active sets that are not on the observed gene list. GO:0046323 (glucose import) and its
relations are highlighted in panel A (grey circle, black lines).
methods, as indicated by the number of genes that are both in the reported
gene list (T2D) and are in at least one of the gene sets inferred to be ac-
tivated (coverage). It does this without increasing the mis-coverage, which
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Table 3
MFA results in type 2 diabetes (T2D) example: 11 GO terms are inferred to be active
using the ILP algorithm to compute the MAP estimate (rows). Basic statistics on these
terms are provided (# T2D-associated genes/set size). The next two columns give the
MCMC-computed marginal posterior activation probabilities for these terms, both using
MGSA and MFA, the constrained alternative. The final column holds the
Benjamini–Hochberg adjusted Fisher-test p-value. All calculations start with 6037 GO
terms (those annotating between 5 and 50 human genes) that together annotate 10,626
human genes. Of the 77 total T2D genes, 58 have at least one annotation to these 6037
GO terms. The inferred gene sets cover 26 of these 58 T2D genes
Gene set (GO term) Statistics P.MFA P.MGSA Fisher
RNA polymerase II core promoter. . . 3/45 0.517 0.028 0.161
Positive regulation of insulin secretion 4/41 0.964 0.372 0.016
Positive regulation of peptidyl-serine. . . 2/35 0.537 0.096 0.756
Negative regulation of insulin secretion 4/23 0.996 0.201 0.003
ER overload response 2/9 0.398 0.159 0.102
Positive regulation of insulin secretion. . . 0/9 0.964 0.002 1.000
Hepatocyte differentiation 2/9 0.316 0.016 0.102
Endodermal cell fate specification 2/8 0.596 0.036 0.091
Exocrine pancreas development 3/8 0.946 0.600 0.003
Negative regulation of protein. . . 2/5 0.420 0.101 0.051
Lamin filament 2/5 0.790 0.400 0.051
is the number of non-T2D genes within the inferred active sets. Figure 3
summarizes the sets found by these methods and reports these coverages.
An interesting set in this case is the GO term glucose import (GO:0046323),
for which the proportion 5/41 of observed T2D genes is very high (small
Fisher p-value), but there is very small posterior activation probability ac-
cording to MFA. That is because the 5 genes are explained more easily as
parts of three other terms in the MAP estimate that have yet other genes
supporting their activation.
A second curious case is GO:0035774, a small term (9 genes) to do with
regulation of insulin secretion. None of these genes was reported to be in-
volved in T2D, however, the set is fully contained in a parent set which is
inferred to be activated by MFA-ILP. As the calculation respects AH, all
subsets of activated sets are activated. This may be a set-level false-positive
call, as none of the contained genes was reported to be T2D associated. MFA
favors the explanation that each of the 9 noncalls was a gene-level false neg-
ative, finding the weight of evidence supporting that interpretation. When
we recall that the gene-level false-negative rate is almost 98% (following
the mixture calculation from Morris et al.), this assessment seems plausible.
We note that for the sake of further simplification of output, it is reason-
able to suppress any such subsets from primary tabulations [see trimming
algorithm, Wang et al. (2014)].
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6.2. RNA interference and influenza-virus replication. In a meta-analysis
of four genome-wide studies of influenza virus, Hao et al. (2013) reported
that 984 human genes had been detected by RNA interference as possibly
being associated with viral replication. As in the T2D example, we com-
pared MFA with MGSA and Fisher’s test on this gene list using 6037 GO
terms annotating between 5 and 50 human genes. Among the 984 influenza-
involved genes, 683 are annotated to at least one of these terms. To apply
the model-based methods, we took advantage of external information on the
false positive rate α and the true positive rate γ [see Wang et al. (2014)].
Figure 4 illustrates the sets found by MFA-ILP, MGSA, and Fisher’s test,
and Tables S5–S8 [Wang et al. (2014)] contain further details of the com-
parative analysis. Again, we find that MFA-ILP dominates the other meth-
ods in terms of gene coverage, with 245 genes explained as compared to
226 (MGSA) and 90 (Fisher) and with mis-coverages 635 (MFA-ILP), 634
(MGSA), and 206 (Fisher). Furthermore, MFA-ILP detects more sets than
MGSA (50 in the trimmed list compared to 30 by MGSA).
To better understand differences between the methods, consider one gene
set GO:0032434, regulation of proteasomal ubiquitin-dependent protein
catabolic process, which annotates 48 human genes, 12 of which were in the
984-list of influenza involved genes (highlighted in Figure 4). The Benjamini–
Hochberg corrected Fisher p-value is 0.017, and so the term would be con-
sidered enriched in the standard analysis; it is also inferred to be active
by MGSA (posterior probability 0.897). But it is not in the MAP estimate
by MFA-ILP and its posterior activation probability is 0.000. Now 10 of
these 12 influenza-involved GO:0032434 genes are part of the child term
GO:0032436, positive regulation of proteasomal ubiquitin-dependent protein
catabolic process, a set of size 31 genes. Both terms are found by the univari-
ate Fisher procedure, exemplifying the redundancy issue; the more specific
term GO:0032436 is identified by MFA-ILP and has high posterior activa-
tion probability. The MFA calculation favors the explanation whereby the
smaller set is activated; this fails to cover two of the 12 GO:0032434 in-
fluenza genes, but it also simplifies the explanation of nonlisted genes in
that set. If the larger set (GO:0032434) is activated, then we have a lot
more mis-covered genes, that is, those in the set but undetected by RNAi
[15 = (48 − 12) − (31 − 10)]. With this example, it may be that the more
specific positive regulation term better characterizes the experimental gene
list.
In Hao et al., gene set analysis was used to show that the four sepa-
rate RNAi studies agreed more substantially than was evident by inspecting
overlaps among the four gene lists. It was applied separately to the study-
specific gene lists, and then the agreement among these four set lists was
measured. For both Fisher’s test and MGSA-ILP, the among-study set-level
agreement was significant according to a simple permutation calibration.
A MULTI-FUNCTIONAL ANALYZER 19
Fig. 4. Sets (GO terms) identified by three methods (A, Fisher’s test; B, MGSA; C,
MFA) as activated to explain the influenza-involved human genes. The layout is as in
Figure 3.
Curiously, the agreement by MGSA was not significant by that measure,
owing primarily to the fact that very few sets were inferred to be active in
the separate studies. The common set-level signal, in conjunction with other
forms of meta-analysis, provided evidence that genome-wide RNAi studies
have higher false-negative rates than false-positive rates.
6.3. Other issues. The full effects of prior choice in model-based gene-set
analysis require further investigation. As to the practical importance of one
choice over another, we do not examine the biological distinctions between
the inferences produced by different methods. A close reading of the T2D
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and RNAi case studies above provides an initial indication of how and why
reported set lists can differ, but assessing the biological significance of these
differences is beyond the present scope. The procedures have distinct sta-
tistical properties and MFA more efficiently captures the functional content
of the reported gene list in terms of model fit. We point out that the dis-
tinctions present themselves when using the relatively complex GO system.
Control calculations show that MGSA and MFA give essentially the same
results when applied to the less complex KEGG system [Figures S1 and S2,
Wang et al. (2014)].
In our comparisons we used MGSA to obtain an estimate of the hyper-
parameter pi, which affects the overall rate of set activity. In order to control
the comparison, we used the same numerical value of pi in the MFA calcu-
lations (in both MFA and MGSA we fixed the other parameters α and γ at
externally derived values). Further improvements of MFA may be possible
using alternative estimates of pi. Other model elaborations which could be
useful in some applications include extending MFA beyond binary Xp and
allowing dependence in gene level measurement errors.
Compute times for MFA depend on the size and content of the gene list,
the incidence matrix I , and the model parameters: MFA-ILP used 2.5 CPU
hours for T2D, and 23 CPU hours for RNAi;9 less time was required for
MFA-MCMC (20 and 45 CPU minutes, resp.).
We have argued that temporal changes in GO reflect an increase in the
complexity of the functional record that justifies the more refined prior dis-
tribution used in MFA (Figure 1). These changes also tell us that the results
of a given analysis naturally depend on the GO version, since the sets in-
volved and the annotations of genes to sets continue to evolve. To assess the
version effect, we applied MFA to four recent GO versions (2010–2013) in
both the T2D and RNAi examples, and using sets annotating between 5 and
50 human genes (GO[5:50]). Table 4 records how similar are time-adjacent
versions of GO as well as how similar are results of MFA. The changes in GO
reflect new terms and new annotations, as well as sets moving in and out of
GO[5:50] as more genes become annotated. Against this substantial evolu-
tion of GO we see that MFA results do also change, but that the changes
are less the more stringent is the marginal posterior probability cutoff.
A feature of MGSA and MFA is that activation of the set implies ac-
tivation of all genes in the set. This strict form of nonnull relationship is
quite different from many univariate methods, which would claim a set is
nonnull if any of its contained genes is nonnull [e.g., the self-contained tests
9R was running on a 4× AMD Opteron(TM) Processor 6174 (48 cores) with 128 GB
RAM.
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Table 4
Version effects: Tabulated are similarity scores comparing set structure and inferred
active sets over time-adjacent versions of GO[5:50]. The collections of sets annotating
between 5 and 50 human genes fluctuate over recent versions of GO. Respectively, in the
four most recent fall versions of Bioconductor, the collections contain 4830, 5546, 6037
and 6488 gene sets. The first row shows the Jaccard index (size of intersection over size
of union) comparing subsequent versions of these gene-set collections. In addition to the
collections changing, the annotations recording which genes are in which sets also change
over time. The second row measures similarity of the sets of annotations. Subsequent
rows show similarity of reported lists of gene sets in the two main examples. In this
comparison, the set is reported if it is in the MAP estimate by MFA-ILP and if its
marginal posterior probability exceeds a threshold (50% or 80%). Inferred active sets
depend to some extent on the GO version in view; setting stronger marginal posterior
thresholds reduces the false-discovery rate and reduces the version effect
2010–2011 2011–2012 2012–2013
Sets 0.72 0.82 0.80
Annotations 0.54 0.70 0.66
T2D 50/MAP 0.33 0.60 0.30
T2D 80/MAP 1.00 0.75 0.60
RNAi 50/MAP 0.72 0.70 0.88
RNAi 80/MAP 0.90 0.79 0.85
of Goeman and Bu¨hlmann (2007)]. It is precisely this relationship, however,
that enables multivariate (i.e., mult-set) analysis, as the role model offers
a straightforward approach to deal with the complex overlaps in the func-
tional record. We note that the role model allows a weaker interpretation;
for instance, we could continue to assert that a gene is activated if it is con-
tained in any activated set, while allowing that only a fraction of activated
genes are nonnull. The difference would be in the tabulation of errors (e.g.,
Xp = 0 might not be a false negative when Ap = 1) and in the interpreta-
tion of α and γ; the family of joint distributions would be the same. As
GO and other repositories record functions of ever more specific gene com-
binations, it is reasonable to expect that a combination of genes relevant in
the cells on test is within the repository. The strict interpretation of activa-
tion is parsimonious and is justified when the repository is sufficiently well
endowed with relevant sets. We performed a small simulation study, using
the T2D data structure, to assess MFA’s ability to recover small activated
sets. In each of 100 simulated cases, we fixed the repository (GO[5:50]), we
randomized the response vector X = (Xp) by appending to the T2D genes a
randomly selected small (5–10 genes) set from GO, and we inferred the acti-
vated sets using MFA. In 91 cases the appended set was identified as active
by MFA-ILP, demonstrating in a limited way the ability of the methodology
to recover signals represented in the repository.
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7. Proofs.
7.1. Proof of Theorem 2.2. Relative to all the sets and parts in the sys-
tem I , we say AH holds if and only if Ap = maxw : p∈wZw for all p and
Zw =minp : p∈wAp for all w. Recall that all Ap and Zw are binary, in {0,1}.
The first condition Ap =maxw : p∈wZw implies Ap ≥Zw for all w with p ∈w;
that Ap achieves the max of the Zw’s has to account for the possibility that
Ap = 1 when all Zw = 0, but this is covered by having Ap ≤
∑
w : p∈wZw.
Thus, the condition Ap = maxw : p∈wZw is equivalent to the first two con-
straints in Theorem 2.2.
To address the second condition, that Zw =minp : p∈wAp for all w, define
a new variable
Tw = 1+
∑
p : p∈w
(Ap − 1),
and notice that Tw = 1 if and only if Ap = 1 for all p ∈w, otherwise Tw ≤ 0.
Observe that the second condition is equivalent to
∑
p : p∈w
(Zw −Ap +1)− Tw ≥ 0(7.1)
since if all Ap = 1, for p ∈ w, then Tw = 1, and Zw must equal 1 to satisfy
(7.1); otherwise, if at least one of the Ap’s equals 0, then Tw ≤ 0, and noting
that the summation in (7.1) is positive confirms the claim. Next, replacing
Tw in (7.1) with its definition, we obtain the third stated inequality∑
p : p∈w
(Zw − 2Ap + 2)≥ 1.
7.2. Proof of the Theorem 4.1. Compared to Zw0 = 0, the possible max-
imal value added to the objective function by letting Zw0 be 1 is c1 +
c3
∑
p∈P+w0
1 (considering parts in P−w0 may already be activated or w0 has
no parts in P−, the best case), however, which is negative since w0 ∈W
∗. So
Zw0 = 0 is preferred toward maximizing the objective function. Next we need
to prove that letting Zw0 = 0 and Ap0 = 0 will not violate the inequalities in
Theorem 2.2.
Denote by W0 and P0 the sets of w0 and p0 satisfying the state in the
theorem, respectively. We claim that for each p0 ∈ P0, {w : Ip0,w = 1} ⊂W0.
If not, then there exists w∗ ∈W ∗ \W0 such that Ip0,w∗ = 1, so w
∗ will be
in W0. This is a contradiction. Thus, Ap0 = max{w : Ip0,w=1}Zw = 0, so the
first two AH inequalities are satisfied. It is readily verified that the third
inequality is also satisfied.
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SUPPLEMENTARY MATERIAL
Supplement: More on role modeling (DOI: 10.1214/14-AOAS777SUPP;
.pdf). We provide further details on violation probabilities, on estimating
false-positive and true-positive error rates, on preparing data for the ILP
algorithm, and on further data analysis findings in the T2D and RNAi ex-
amples.
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